Nuffer W, Williams B, Trujillo JM
This changes the charge and structure of the peptide at that position, potentially disrupting biological activity
Animal studies have shown promising results for metabolic health, but translation to human clinical benefit has not been definitively established
This trifecta addresses the most common barriers to fat loss : activating fat burning (SLU-PP-332), enhancing energy (5-Amino-1MQ), and accelerating repair (BPC-157)
Limitations to this study include that there were uncontrolled confounding factors, as well as bias secondary to self-selection of treatment
Notably, FGF21 analogs have reduced insulin resistance or decreased liver fat in clinical trials 16,26